NETest Supporting Data
The NETest is a novel blood-based laboratory developed test (LDT), a molecular diagnostic, that provides sensitive and specific information with respect to a neuroendocrine tumor status. The test is unique in that it uses 51 neuroendocrine tumor gene transcripts and novel state-of-the-art molecular biomarker analyses developed by Wren scientists. This allows us to monitor neuroendocrine tumor gene activity levels.
The NETest is:
- A circulating fingerprint developed from analyses of neuroendocrine tumor transcriptomes (1-3).
- A multianalyte analytic algorithm (MAAA) that captures the hallmarks of neuroendocrine tumor biology (3,4).
- Highly sensitive and specific for detecting neuroendocrine tumor disease (3-6).
- More sensitive than single analyte ELISAs for detecting disease (4-7).
- More sensitive than measuring chromogranin A for evaluating neuroendocrine tumor disease status (4-7).
- Unaffected by concomitant PPI use (6-7).
Clinically, NETest scores:
- Accurately diagnose neuroendocrine tumor disease (4-7).
- Provides biochemical assessment of the extent of surgical cytoreduction (8).
- Accurately defines stable and progressive disease (9,10).
- Identifies stable and progressive clinical disease activity during somatostatin analog therapy treatment (9,10).
- Can identify biochemical evidence of neuroendocrine tumor disease recurrence prior to topographic (CT/MRI) or functional imaging (68Gallium PET or Octreoscan) (10-11).
A combination of grade and 8 NETest genes (PPQ - PRRT predictive quotient) can predict the efficacy of peptide receptor radiotherapy (PRRT) and monitor tumor response (11).
- (1) Kidd M, Modlin IM, Drozdov I: Gene network-based analysis identifies two potential subtypes of small intestinal neuroendocrine tumors. BMC Genomics 2014; 15:595.
- (2) Kidd M, Modlin IM, Mane SM, Camp RL, Eick G, Latich I: The role of genetic markers—NAP1L1, MAGE-D2, and MTA1-- in defining small-intestinal carcinoid neoplasia. Annals of Surgical Oncology 2006; 13:253-262.
- (3) Kidd M, Drozdov I, Modlin IM. Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status. Endocrine Related Cancer. 2015; 22:561-75.
- (4) Modlin I, Drozdov I, Kidd M: The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLOS One 2013; e63364.
- (5) Modlin I, Drozdov I, Alaimo D, Callahan S, Teixeira N, Bodei L, Kidd M: A multianalyte PCR blood test outperforms single analyte ELISAs for neuroendocrine tumor detection Endocrine Related Cancer 2014;21:615-628.
- (6) Modlin IM, Kidd M, Bodei L, Drozdov I, Aslanian H. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract. American Journal of Gastroenterology 2015; 110:1223-32.
- (7) Modlin I, Aslanian H, Bodei L, Drozdov I, Kidd M: A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by PPIs. Endocrine Connections 2014; 3:215-23.
- (8) Modlin IM, Frilling A, Salem RR, Alaimo D, Drymousis P, Wasan HS, Callahan S, Faiz O, Weng L, Teixeira N, Bodei L, Drozdov I, Kidd M. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies. Surgery. 2016; 159:336-47.
- (9) Ćwikła JB, Bodei L, Kolasinska-Ćwikła A, Sankowski A, Modlin IM, Kidd M. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy. Journal Clinical Endocrinology Metabolism. 2015; 100:E1437-45.
- (10) Pavel M, Jann H, Prasad V, Drozdov I, Modlin IM, Kidd M. NET blood transcript analysis defines the crossing of the clinical Rubicon: when stable disease becomes progressive. Neuroendocrinology 2016 Apr 15 (published online).
- (11) Bodei L, Kidd M, Modlin IM, Severi S, Drozdov I, Nicolini S, Kwekkeboom DJ, Krenning EP, Baum RP, Paganelli G. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging. 2016, 43:839-51.